Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. Investment Status. intarcia.com | BioTech | Funding to Date: $961,464,514. Intarcia Therapeutics, a Boston-based company looking to revolutionize treatment for Type … $75,000,000 Debt financing MassDevice. About Intarcia Therapeutics, Inc.Intarcia Therapeutics, Inc. is an independent, privately held, biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Other executives include Bryan Roberts, Director; Thomas Alessi, Vice President, Development and Manufacturing and 9 others. Intarcia Therapeutics has filed for FDA approval of its osmotic mini-pump Type 2 diabetes treatment. The company has not officially endorsed a plan to participate in an IPO. The biopharmaceutical company had filed for an offering of 5 million shares at an estimated price of $12 to $14 each. The well-funded company has said publicly it is unlikely to seek an initial public offering prior to commercialization of its lead product for fear of leaving value on the table. There are currently no open jobs at Intarcia Therapeutics listed on Glassdoor. Private. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. BOSTON, Oct. 8, 2019 /PRNewswire/ -- Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its new drug application (NDA) for ITCA 650 (exenatide implant), for the treatment of type 2 diabetes mellitus.... Oct 8, 2019. www.prnewswire.com. Diabetes ‘Unicorn’ Raises Final VC Round Before IPO. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation . Cullinan Management (CGEM) intends to raise $150 million from the sale of its common stock in an The Intarcia DUROS drug delivery platform stabilizes and delivers therapeutic proteins and peptides. Private Healthcare, Therapeutics-Biologics. Baillie Gifford is not the only fund coming into life sciences and healthcare investments with big dollars and long-term views. Underwriters for Intarcia Therapeutics Inc. on Friday set the terms of the company's pending initial public offering at five million shares with an estimated price range of $12 to $14 a share. Pros. " Their lead drug candidate, ITCA 650, is a treatment for Type 2 diabetes that is currently in Phase 3 clinical trials. Intarcia Therapeutics Inc Intarcia Therapeutics, Inc. operates as a biopharmaceutical company. Intarcia is committed to unleashing new ways to treat and prevent chronic disease. We are developing a pipeline of innovative therapies that merge medicine with technology to help transform therapeutic categories in chronic diseases. Interested in learning more about how Intarcia is carrying out its vision? Company sites Boston and Hayward have completely different cultures " (in 7 reviews) " No one there knows what they are doing " (in 6 reviews) More Pros and Cons. The deal was initially expected to price on Tuesday. On Feb. 7, Intarcia filed an IPO to sell up to $86.25 million in … Less than two months before the FDA rejected Intarcia Therapeutics’ potential blockbuster treatment for type 2 diabetes last year, inspectors at … The pros to this place was working with a great manufacturing team on Dayshift. Intarcia Therapeutics scraps IPO. Doesn't Recommend. Intarcia is developing innovative therapies, merging medicine and technology. Beyond bringing Intarcia yet more instant cash, the $225m royalty financing the private group pulled off this week looks like an unusual way of putting a real valuation both on itself and its key asset, the exenatide-secreting implant ITCA 650. Intarcia Therapeutics's Chairman, President and CEO is Kurt Graves. They're struggling getting the drug approved by the FDA. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. Overall, it's a good company. At a time when biotechnology companies in even earlier stages of clinical development are choosing to IPO in record numbers, it is interesting that Intarcia has Year Funded. Sector. Negative Outlook. Pros. intarcia.com | BioTech | Founded: 1997 | Funding to Date: $961,464,514. I worked at Intarcia Therapeutics full-time for more than 3 years. Less than two months before the FDA rejected Intarcia Therapeutics ’ potential blockbuster treatment for type 2 diabetes last year, inspectors at the agency faulted the Boston-based company for a litany of manufacturing issues and warned about potential drug contamination, a newly-obtained document shows. Hands on experience in SEC and IPO related filings including Form 10K. Cons. References in this prospectus to "we," "us" and "our" refer to Intarcia Therapeutics, Inc. Our Company . Intarcia Therapeutics Stock. 10Q, S-1 and other registration statement filings. In February 2018, Intarcia CEO Kurt Graves told the Business Journal that the company hoped to resubmit its approval application around mid-year. But as of late September — the one-year anniversary of the rejection — a company spokesperson said Intarcia still had not submitted that application. In September 2017 the FDA rejected ITCA 650 due to concerns regarding manufacturing issues. We would like to show you a description here but the site won’t allow us. The Company develops and commercializes therapies to enhance treatment outcomes. This week the U.S. Food and Drug Administration (FDA) issued its second Complete Response Letter for the device. Phone Number 617-936-2500. 2003. Intarcia Therapeutics has a great product that will help many people " (in 6 reviews) " good pay, nice team environment " (in 5 reviews) Cons. " Dubbed a biotech "unicorn" due to its lofty valuation, Intarcia has a strong cash position, raising over $600 million through September in a private equity financing. Senior Buyer Intarcia Therapeutics (Current Employee) - Hayward, CA - February 3, 2020. Sector. Intarcia is a biotech company dedicated to redesigning the … Intarcia Therapeutics IPO. Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to improving real-world adherence and real-world outcomes in some of our nation’s most costly and devastating chronic diseases by leveraging the convergence of medicines and novel delivery technologies. Intarcia is a biotech company focused on developing innovative therapies utilizing a proprietary delivery system – medicines that have the potential to … Its flagship product, Medici Drug Delivery System, has the potential to transform the prevention and management of serious chronic diseases. Intarcia develops therapies for diseases that require long-term chronic treatment such as Type 2 diabetes. Intarcia Therapeutics is a biopharmaceutical company that provides a variety of services in addition to its proprietary products. Intarcia Therapeutics Closes $215M First Close of Equity Financing Funding Health. The toxic environment from working with the swing shift and the politics. Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. The company offers research and development, manufacturing, marketing and distribution services. investors to fully recoup their investment, and in the meantime, Intarcia undertakes no immediate debt or payment obligations and no immediate dilution. Intarcia Therapeutics Inc. is withdrawing its initial public offering due to poor market conditions, the company announced late … It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Everything.”. Intarcia Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops and commercializes therapies to enhance treatment outcomes. Intarcia Therapeutics serves patients throughout the United States. NO. OF EMPLOYEES Aims Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks. The submission triggered a $100 million payment, giving Intarcia some of … The Baillie Gifford portfolio alone contains Ginkgo, Flatiron and Intarcia along with therapeutics companies CureVac, Denali Therapeutics and UNITY Biotechnology. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. “Everything you do as a company—everything you say, how you express yourself—counts. Boston-based Intarcia continues to run into a regulatory roadblock concerning its implanted diabetic pump ITCA 650. ITCA 650 Intarcia Therapeutics, Inc. 15 Sep 2016. Intarcia Therapeutics is a biopharmaceutical company developing therapies for chronic diseases. Diabetes ‘Unicorn’ Raises Final VC Round Before IPO Intarcia Therapeutics, Inc. 15 Sep 2016. Disapproves of CEO. Boston-based Intar­cia Ther­a­peu­tics be­came the lat­est ca­su­al­ty of the FDA’s man­u­fac­tur­ing stan­dards. Before joining the Company, Ray served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Intarcia Therapeutics, Inc. from September 2013 through April 2020. After addressing those concerns, Intarcia resubmitted its … ZELTIQ is focused on developing products utilizing its proprietary controlled-cooling technology. Sign up to get notified as soon as new Intarcia Therapeutics jobs are posted. Intarcia Therapeutics was founded in 1997 by David Franklin, James M. Ahlers, and Thomas Alessi. See the full leadership team at Craft. Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. FinSMEs. Tags: Phase 3 Financing - Company secures $225M financing in exchange for 1.5% of future global net sales of ITCA 650, a novel once or twice yearly and injection-free GLP-1 therapy currently in phase 3 clinical development to treat type 2 diabetes. The initial public offering of Intarcia Therapeutics Inc. was pulled due to market conditions, an underwriter said on Wednesday. Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. Once they go commercial they my open up more jobs. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis. UNLOCKING LIFE’S POSSIBLITIES: Intarcia Therapeutics. Wish they had more room for growth, but at the moment they do not. Intarcia is much further along than that—ITCA 650 is in the midst of an extensive Phase 3 program in type 2 diabetes.
intarcia therapeutics ipo 2021